ACTU
NASDAQ
$1.40
Actuate Therapeutics Inc (ACTU)
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $9.98 (+612.86%)
Market Cap
$41M
Free Cash Flow Yield
-48.07%
Beta (5Y)
1.02
Price Chart
Valuation
Market Cap$41M
P/B10.87
Profitability
EBITDA-$22M
EPS-$0.96
Financial Health
Free Cash Flow Yield-48.07%
Growth & Risk
Beta (5Y)1.02
Sharpe Ratio-1.13